Key Highlights

  • Tempus AI (NASDAQ:TEM) was trading down 7.51% at USD 70.19 on Friday, November 13, 2026, implying a prior close near USD 75.89 (calculated), against USD 72.22 at the October 30, 2026 close in market data.
  • Third-quarter revenue, reported November 2, 2026, was USD 411.5 million, up 23%, with Gross Profit of USD 266.7 million, a 64.8% gross margin.
  • Adjusted EBITDA was USD 25.6 million against USD 1.5 million a year earlier, and the net loss narrowed to USD 14.9 million from USD 80.0 million.
  • Full-year 2026 Revenue guidance was raised to USD 1.60 billion to USD 1.605 billion, about 25% growth, while adjusted EBITDA guidance of about USD 65 million was unchanged.

A 7.51% Slide Without a Company Announcement

Tempus AI (NASDAQ:TEM) was trading down 7.51% at USD 70.19 on Friday, November 13, 2026, in market data. No company announcement explaining the move was found among items dated November 11 to 13, so the change is the figure of record only for the live session. The latest company event is the third-quarter report of November 2, 2026. Market data showed a 52-week range of USD 40.77 to USD 91.83 and a close of USD 72.22 on October 30, after a 7.22% fall that day, so sharp daily swings are not new for this stock. Market Value was listed near USD 13.03 billion at the October 30 close, and today's price implies roughly USD 12.7 billion on an unchanged share count of about 180.43 million (calculated).

What the Third Quarter Showed

Tempus AI sells AI-enabled precision medicine services, including genomic testing and data licensing to drug developers. Revenue of USD 411.5 million rose 23%, gross profit rose 27% and adjusted EBITDA reached USD 25.6 million. The net loss of USD 14.9 million compares with USD 80.0 million a year earlier, and cash and marketable securities were USD 854.4 million. Guidance for 2026 revenue was lifted to USD 1.60 billion to USD 1.605 billion, about USD 1.6 billion at the midpoint, while adjusted EBITDA stayed near USD 65 million, so the raise did not come with higher profit guidance. Gross profit grew faster than revenue, 27% against 23%, a gap the release extract does not explain by segment, and a published summary put data unit growth near 33%.

Data Licensing, Pharma Ties and the Risks

The company expanded a multi-year data license with Bristol Myers Squibb through 2031 on October 23, 2026, and announced collaborations on cancer and Alzheimer's Drug Development in October. Trailing net loss was USD 254.43 million in market data, and about 180.43 million shares were outstanding. Risks include continued GAAP losses, reimbursement and regulatory exposure in testing, and dependence on pharma contracts. Several AI-related stocks are among the day's decliners, but no verified sector driver for November 12 to 13 was found, so no cause for today's drop is confirmed. Ambry Genetics, its genetic testing subsidiary, also launched whole-genome sequencing for rare disease on October 13, per market data.

Where Things Stand

No cause for the 7.51% decline was found, and it may be tied to swings across AI-labelled stocks rather than company news. Tempus AI (NASDAQ:TEM) reported 23% revenue growth, a much smaller net loss, positive adjusted EBITDA and a raised revenue outlook, but still lost money on a GAAP basis. The next markers are fourth-quarter results, pharma data-license renewals and progress toward the unchanged adjusted EBITDA goal.